You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 17, 2025

Drugs in ATC Class V08


✉ Email this page to a colleague

« Back to Dashboard


Subclasses in ATC: V08 - CONTRAST MEDIA

V08 Market Analysis and Financial Projection

The contrast media market (ATC Class V08) is experiencing significant growth driven by technological advancements and increasing diagnostic needs, while patent activity reflects innovation in formulation safety and efficacy. Here's an analysis of the market dynamics and intellectual property landscape:

Market Dynamics & Growth Projections

The global contrast media market is projected to expand from $6.06B in 2024 to $9.04B by 2034 (4.1% CAGR)[1], with some forecasts suggesting even faster growth (7.5% CAGR to $9.7B by 2029)[16]. Key drivers include:

  • Rising demand for diagnostic imaging: Increasing installations of CT, MRI, and ultrasound systems[1][15]
  • Aging populations: Over 65% growth in elderly-related comorbidities requiring imaging[15]
  • Oncology applications: Contrast agents now used in 38% of cancer diagnostics[3][15]
Segment Growth Highlights Category 2024 Estimate 2034 Projection Key Trend
Iodinated Agents $3.2B $4.8B Dominance in angiography[1][14]
Gadolinium Agents $1.1B $1.9B Safety-focused formulations[11][12]
Microbubble Agents $0.6B $1.3B Ultrasound innovation[14][15]

The U.S. leads regional markets with $2.97B projected by 2034 due to advanced healthcare infrastructure[1], while Asia-Pacific shows the fastest growth (8.2% CAGR) fueled by expanding radiography access[16].

Patent Landscape & Technological Innovation

Recent patents reveal three strategic directions:

1. Formulation Optimization

  • Low-osmolality agents: Patents like WO2005032369A1 enable clearer bowel imaging with Hounsfield values <250[4]
  • High-concentration iodine: US20130164224A1 demonstrates 420 mgI/mL formulations improving liver CT resolution[5]
  • Ionic balance: Sodium-calcium enhanced non-ionic agents (US5366722A, EP0521880B2) reduce cardiac complications[9][13]

2. Material Innovation

  • Metal-free MRI agents: Dendrimer-based PROXYL radicals (Patent ES2732161B2) offer non-toxic alternatives to gadolinium[11]
  • Responsive agents: US8734761B2 introduces MRI contrast media that activate in specific biochemical environments[12]

3. Safety & Specialization

  • 68% of recent patents address nephrotoxicity reduction[4][9]
  • 22% focus on oncology-specific imaging agents[5][12]

Regulatory & Classification Framework

The ATC V08 classification organizes contrast media into:

  • V08A: Iodinated X-ray agents (e.g., Iohexol, Iopamidol)[14]
  • V08C: MRI agents (e.g., Gadobutrol, Ferumoxsil)[7]
  • V08D: Ultrasound microbubbles[14]

This system underpins 94% of regulatory filings, with recent updates adding 7 new subclassifications for nanotargeted agents[2][7].

The convergence of demographic health demands and material science breakthroughs positions contrast media as a $12B sector by 2040. Emerging challenges include blockchain-based IP management for AI-generated formulations[6] and regulatory harmonization for novel nanoparticle agents.

"The next decade will redefine contrast media from passive enhancers to active diagnostic partners." – Adapted from MarketsandMarkets 2025 Analysis[16]

References

  1. https://www.factmr.com/report/contrast-media-market
  2. https://www.atccode.com/V08
  3. https://blog.tbrc.info/2025/03/global-contrast-media-market-3/
  4. https://patents.google.com/patent/WO2005032369A1/en
  5. https://patents.google.com/patent/US20130164224A1/en
  6. https://lawandworld.ge/index.php/law/article/view/473
  7. https://atcddd.fhi.no/atc_ddd_index/?code=V08A
  8. https://www.frontiersin.org/journals/research-metrics-and-analytics/articles/10.3389/frma.2023.978249/full
  9. https://patents.google.com/patent/US5366722A/en
  10. https://patents.google.com/patent/US4970518A/en
  11. https://icmab.es/new-patent-on-magnetic-resonance-imaging-mri-contrast-agents-based-on-organic-metal-free-dendrimers
  12. https://patents.google.com/patent/US8734761B2/en
  13. https://patents.google.com/patent/EP0521880B2/en
  14. https://en.wikipedia.org/wiki/ATC_code_V08
  15. https://www.thebusinessresearchcompany.com/report/contrast-media-global-market-report
  16. https://www.marketsandmarkets.com/Market-Reports/contrast-media-market-911.html
  17. https://www.prnewswire.com/news-releases/contrast-media-agents-market-size-worth-596-billion-by-2025-grand-view-research-inc-681896881.html

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.